Published in Blood on April 26, 2010
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood (2012) 1.81
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica (2011) 1.31
Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J (2011) 1.19
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) (2012) 1.12
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J (2012) 1.09
Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol (2011) 1.08
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res (2013) 1.03
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia (2011) 1.01
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood (2012) 0.97
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res (2012) 0.96
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther (2013) 0.94
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol (2011) 0.90
The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front Genet (2013) 0.89
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica (2014) 0.87
Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1α. BMC Biochem (2014) 0.85
Endoplasmic reticulum quality control in cancer: Friend or foe. Semin Cancer Biol (2015) 0.83
Interplay between unfolded protein response and autophagy promotes tumor drug resistance. Oncol Lett (2015) 0.82
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. Semin Cancer Biol (2015) 0.82
A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability. Oncotarget (2011) 0.81
High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol (2015) 0.80
XBP1s Links the Unfolded Protein Response to the Molecular Architecture of Mature N-Glycans. Chem Biol (2015) 0.77
The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res (2014) 0.77
Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget (2016) 0.77
Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway. BMC Cancer (2015) 0.76
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors. J Leuk (Los Angel) (2015) 0.76
Understanding the multiple biological aspects leading to myeloma. Haematologica (2014) 0.76
Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. Mol Cancer Ther (2016) 0.75
Endoplasmic Reticulum Proteostasis: A Key Checkpoint in Cancer. Am J Physiol Cell Physiol (2016) 0.75
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response. Sci Rep (2016) 0.75
Increase in gene-transcript levels as indicators of up-regulation of the unfolded protein response in spontaneous canine tumors. Can J Vet Res (2014) 0.75
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis (2017) 0.75
Physiological/pathological ramifications of transcription factors in the unfolded protein response. Genes Dev (2017) 0.75
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Recent improvements to the SMART domain-based sequence annotation resource. Nucleic Acids Res (2002) 25.06
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Preventing the return of fear in humans using reconsolidation update mechanisms. Nature (2009) 5.82
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains. Trends Biochem Sci (2003) 5.19
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol (2006) 4.32
A memory retrieval-extinction procedure to prevent drug craving and relapse. Science (2012) 4.04
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol (2008) 3.33
Validity of composite end points in clinical trials. BMJ (2005) 3.26
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Heritability and tissue specificity of expression quantitative trait loci. PLoS Genet (2006) 2.80
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation (2013) 2.73
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol (2007) 2.53
Psychopathology among New York city public school children 6 months after September 11. Arch Gen Psychiatry (2005) 2.48
Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol (2006) 2.45
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med (2008) 2.44
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials (2005) 2.40
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
Energy expenditure of sedentary screen time compared with active screen time for children. Pediatrics (2006) 2.29
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
ARL1, a LOB-domain protein required for adventitious root formation in rice. Plant J (2005) 2.24
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med (2003) 2.20
Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet (2003) 2.16
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract (2013) 2.12
Herpes simplex virus glycoproteins gB and gH function in fusion between the virion envelope and the outer nuclear membrane. Proc Natl Acad Sci U S A (2007) 2.07
OsPHR2 is involved in phosphate-starvation signaling and excessive phosphate accumulation in shoots of plants. Plant Physiol (2008) 2.06
Design, analysis, and presentation of crossover trials. Trials (2009) 2.01
Two rice phosphate transporters, OsPht1;2 and OsPht1;6, have different functions and kinetic properties in uptake and translocation. Plant J (2008) 1.97
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
The morphogenesis of feathers. Nature (2002) 1.91
Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth Analg (2007) 1.91
Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res (2011) 1.90
An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol (2005) 1.89
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci U S A (2008) 1.79
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood (2012) 1.79
A PIN1 family gene, OsPIN1, involved in auxin-dependent adventitious root emergence and tillering in rice. Plant Cell Physiol (2005) 1.79
Altered fear learning across development in both mouse and human. Proc Natl Acad Sci U S A (2012) 1.77
The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77
OsPTF1, a novel transcription factor involved in tolerance to phosphate starvation in rice. Plant Physiol (2005) 1.76
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 1.74
Cell wall polysaccharides are specifically involved in the exclusion of aluminum from the rice root apex. Plant Physiol (2007) 1.72
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol (2011) 1.71
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Adaptation to the sky: Defining the feather with integument fossils from mesozoic China and experimental evidence from molecular laboratories. J Exp Zool B Mol Dev Evol (2003) 1.69
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65